Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database

Therapeutic Innovation and Regulatory Science

Volumn 52, Issue 3, 2018, Pages 339-347

  Matsuoka, Yomei ^a   Narukawa, Mamoru ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

antirheumatic agent; JADER; reporting odds ratio; SAE; serious adverse event; time to onset

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BILIARY TRACT TUMOR; BONE MARROW DISEASE; BREAST TUMOR; CLINICAL PRACTICE; CONTROLLED STUDY; CYTOPENIA; DATA BASE; DISEASE ASSOCIATION; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; HUMAN; JAPANESE (PEOPLE); LEUKOPENIA; LIVER CANCER; LIVER TUMOR; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MIDDLE AGED; ODDS RATIO; OVARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RHEUMATOID ARTHRITIS; RISK REDUCTION; SKIN CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TUBERCULOSIS; UTERINE TUBE TUMOR; UTERUS CANCER; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; FACTUAL DATABASE; JAPAN; NEOPLASM; TIME FACTOR;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIRHEUMATIC AGENTS; BONE MARROW DISEASES; DATABASES, FACTUAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INTERLEUKIN-6; JAPAN; METHOTREXATE; NEOPLASMS; ODDS RATIO; TIME FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85042443570     PISSN: 21684790     EISSN: 21684804     Source Type: Journal    
DOI: 10.1177/2168479017728987     Document Type: Article

References (25)

1. Berghen N, Teuwen LA, Westhovens R, Verschueren P. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study. Clin Rheumatol. 2015;34:1687–1695.
2. Liu Y, Fan W, Chen H, Yu MX. Risk of breast cancer and total malignancies in rheumatoid arthritis patients undergoing TNF-α antagonist therapy: a meta-analysis of randomized control trials. Asian Pac J Cancer Prev. 2014;15:3403–3410.
3. Salk A, Stobaugh DJ, Deepak P, Ehrenpreis ED. Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System. Drug Saf. 2013;36:329–334.
4. Krishnan A, Stobaugh DJ, Deepak P. Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatol Int. 2015;35:661–668.
5. Deepak P, Stobaugh DJ, Sherid M, Sifuentes H, Ehrenpreis ED. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther. 2013;38:388–396.
6. Japan Pharmaceuticals and Medical Devices Agency. Japanese adverse drug event report database (JADER) [in Japanese]. http://www.info.pmda.go.jp/fukusayoudb/CsvDownload.jsp. Accessed February 19, 2017.
7. Nomura K, Takahashi K, Hinomura Y. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Design Dev Ther. 2015;9:3031–3041.
8. Sasaoka S, Matsui T, Abe J. Evaluation of the association of hand-foot syndrome with anticancer drugs using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases [in Japanese]. Yakugaku Zasshi. 2016;136:507–515.
9. Nakamura M, Umetsu R, Abe J. Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. J Pharm Health Care Sci. 2015;1:34–42.
10. Kobayashi T. Comparative study of the time period between the initiation of various interferon therapies and the onset of suicide- or diabetes-related side effect [in Japanese]. Bull Natl Inst Health Sci. 2013;131:45–49.
11. Yamada M, Handa J. Comparison of the onset time profile among the interferon formulations in adverse drug reaction of suicide- or diabetes related [in Japanese]. Jpn J Pharmacoepidemiol. 2014;19:23–30.
12. Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–396.
13. Japan College of Rheumatology (2017) guidelines for use of TNF inhibitors [in Japanese]. http://www.ryumachi-jp.com/info/guideline_TNF.html. Accessed April 4, 2017.
14. Japan College of Rheumatology (2017) guidelines for use of tocilizumab [in Japanese]. http://www.ryumachi-jp.com/info/guideline_tcz.html. Accessed November 23, 2016.
15. Japan College of Rheumatology (2011) guidelines for use of methotrexate [in Japanese]. http://www.ryumachi-jp.com/info/newsMTX-text_2011.html. Accessed November 23, 2016.
16. MedDRA. https://www.meddra.org/. Accessed May 27, 2017.
17. MedDRA Maintenance and Support Services Organization. “Introductory Guide for Standardized MedDRA Queries (SMQs) Version 19.1.” https://www.meddra.org/sites/default/files/guidance/file/smq_intguide_19_1_english.pdf. Published 2016. Accessed May 27, 2017.
18. van Puijenbroek EP, Diemont WL, van Grootheest K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf. 2003;26:293–301.
19. van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3–10.
20. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68:1–26.
21. Japan College of Rheumatology. Guidelines for the management of rheumatoid arthritis, Japan College of Rheumatology 2014 [in Japanese]. Japan: Medicalreview; 2014.
22. Wu CY, Chen DY, Shen JL. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. Arthritis Res Ther. 2014;16:449–460.
23. Matsuda S, Aoki K, Kawamata T. Bias in spontaneous reporting of adverse drug reactions in Japan. PLoS One. 2015;10:e0126413.
24. Hoffman KB, Demakas AR, Dimbil M, Tatonetti NP, Erdman CB. Stimulated reporting: the impact of US Food and Drug Administration-issued alerts on the Adverse Event Reporting System (FAERS). Drug Saf. 2014;30:891–898.
25. Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37:283–294.